{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"6"}]}],"title":"At Least 1 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"6"}]}],"title":"At Least 1 Related TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"}]}],"title":"At Least 1 Grade >=3 TEAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"}]}],"title":"At Least 1 SAE"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"}]}],"title":"At Least 1 DLT"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"}]}],"title":"At Least 1 TEAE Leading to Death"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"}]}],"title":"At Least 1 TEAE Leading to Premature Treatment DC"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"14"},{"groupId":"OG003","value":"6"}],"units":"Participants"}],"description":"Safety and tolerability of IMO-8400 in patients with Waldenstrom's Macroglobulinemia: Assessment of adverse events","groups":[{"description":"IMO-8400 0.6 mg/kg once weekly s.c.","id":"OG000","title":"IMO-8400 0.6 mg/kg 1x/wk"},{"description":"IMO-8400 1.2 mg/kg once weekly s.c.","id":"OG001","title":"IMO-8400 1.2 mg/kg 1x/wk"},{"description":"IMO-8400 1.2 mg/kg twice weekly s.c.","id":"OG002","title":"IMO-8400 1.2 mg/kg 2x/wk"},{"description":"IMO-8400 2.4 mg/kg once weekly s.c.","id":"OG003","title":"IMO-8400 2.4 mg/kg 1x/wk"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Safety Population","reportingStatus":"POSTED","timeFrame":"Up to 24 weeks","title":"Safety and Tolerability of IMO-8400 in Patients With Waldenstrom's Macroglobulinemia","type":"PRIMARY","unitOfMeasure":"Participants"}